20412 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring heteroatoms, e.g. piperazine Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
Piperidine derivatives for GPR119 agonist
#2402Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors
#2403Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
#2404Cytomegalovirus inhibitor compounds
#2405Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
#2406SOLID PHARMACEUTICAL FORMULATION WITH DELAYED RELEASE
#2407Methods for treatment of Parkinson's disease
#2408Optogenetic inhibition of overactive neuronal activity
#2409Selective inhibitors of undifferentiated cells
#2410Drug for preventing/treating ocular disease
#2411Methods of use comprising deuterated pyrazino[2,1-a]isoquinolines
#2412Inhibitors of bruton's tyrosine kinase
#2413FLUOROERGOLINE DERIVATIVES AND USES THEREOF
#2414Azetidinyloxyphenylpyrrolidine compounds
#2415Fused ring compound for use as mineralocorticoid receptor antagonist
#2416BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE
#2417Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors
#2418BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF GASTROINTESTINAL INFECTIONS
#2419JAK1 SELECTIVE INHIBITOR AND USES THEREOF
#2420PYRAZOLE DERIVATIVES AS JAK INHIBITORS
#2421Quinolinyl modulators of RORγt
#2422Crystalline forms of a dipeptidyl peptidase-IV inhibitors
#2423Fluoroergoline analogs
#2424IN SITU GEL LOADED WITH PHOSPHODIESTERASE TYPE V INHIBITORS NANOEMULSION
#2425Benzoxepin PI3K inhibitor compounds and methods of use
#2426Fused 2-aminothiazole compounds
#2427Alkylated piperazine compounds
#2428Inhibitors of protein kinases
#2429Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
#2430Dietary fiber compositions with metformin, sitagliptin, or a combination thereof for the treatment of metabolic disease
#2431Liver X receptor modulators
#2432NOVEL COMPOSITIONS AND METHODS
#2433Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
#2434Dissolvable dietary supplement strip and methods for using the same
#2435D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders
#2436Methods
#2437Composition for prophylaxis or treatment of vascular or cardiac valvular calcification comprising dipeptidyl peptidase-4 inhibitor
#2438Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
#2439Liver X receptor modulators
#2440Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
#2441Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
#2442N-substituted hetero-bicyclic furanone derivatives for combating animal
#2443Biaryl acetamide compounds and methods of use thereof
#2444METHOD OF THERAPEUTIC ADMINISTRATION OF DHE TO ENABLE RAPID RELIEF OF MIGRAINE WHILE MINIMIZING SIDE EFFECT PROFILE
#2445Substituted pyrrolo[1,2-A]pyrazin-1-ones and pyrazolo[1,5-A]pyrazin-4-ones as inhibitors of tankyrase and poly(ADP-ribose)polymerase activity
#2446Liver X receptor modulators
#2447TRIAZOLOPYRAZINE DERIVATIVES
#2448Pyrazine amide compounds
#2449Crystalline form of sitagliptin sulfate
#2450COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING MUCOSITIS AND WEIGHT LOSS
#2451Substituted quinoxalines as FGFR kinase inhibitors
#2452COMBINATION OF LIVER X RECEPTOR MODULATOR AND ESTROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF AGE-RELATED DISEASES
#2453Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP)
#2454Phenylimidazole derivatives as PDE10A enzyme inhibitors
#2455Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
#2456Treatment for melanoma
#2457Method of Using Dihydroergotamine for Pre-emptive Treatment of Migraine
#2458COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS
#2459Methods of treatment using pyridinonyl PDK1 inhibitors
#2460Substituted pyrrolo[1,2-a]piperazines and pyrrolo[1,2-a][1,4]diazepines as neurokinin 1 receptor antagonists
#2461Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
#2462Benzyl piperidine compounds as lysophosphatidic acid (LPA) receptor antagonist
#2463Heteroaryl pyridone and aza-pyridone amide compounds
#2464METHODS AND SYSTEMS FOR TREATMENT OF MIGRAINES AND OTHER INDICATIONS
#2465Substituted imidazopyrazines as Akt kinase inhibitors
#2466Drug Delivery Technology
#2467IP receptor agonist heterocyclic compounds
#2468Heteroaryl pyridone and aza-pyridone compounds
#2469PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS
#2470Sublingual films
#2471Therapeutic approaches for treating parkinson's disease
#2472Kappa opioid receptor effectors and uses thereof
#2473NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
#2474Methods of treating disease-induced ataxia and non-ataxic imbalance
#2475Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof
#2476COMBINATION THERAPY COMPRISING SGLT INHIBITORS AND DPP4 INHIBITORS
#2477Derivatives of Betulin
#2478Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
#2479IP receptor agonist heterocyclic compounds
#2480Substituted imidazo[2,1-A]isoindoles as PDE10 inhibitors
#2481COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS
#2482Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use
#2483Piperazinyl derivatives for the treatment of cancer
#2484Methods of Use of Inhibitors of Phosphodiesterases and Modulators of Nitric Oxide, Reactive Oxygen Species, and Metalloproteinases in the Treatment of Peyronie's Disease, Arteriosclerosis and Other Fibrotic Diseases
#2485COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION
#2486Compositions for oral administration to animals, processes for obtaining the same and the uses thereof
#2487Particulate materials
#2488Inhibitors of the renal outer medullary potassium channel
#2489COMPOSITIONS COMPRISING POMEGRANATE POLYPHENOLS IN COMBINATION WITH ERECTILE DYSFUNCTION-TREATING COMPOUNDS, AND METHODS OF TREATING ERECTILE DYSFUNCTION THEREWITH
#2490N-substituted heterocyclyl carboxamides
#2491Heterocyclic amides compounds which are HDAC6 inhibitors and used as anti-tumoral agents
#2492DISSOLVING SOLID SOLUTION PERFORATOR PATCH FOR MIGRAINE TREATMENT
#2493Substituted pteridinones for the treatment of cancer
#2494Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders
#2495Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-one
#2496Treatment of cancer with dihydropyrazino-pyrazines
#2497Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
#2498Methods for treating cancer using TOR kinase inhibitor combination therapy
#2499Methods for treating cancer using TOR kinase inhibitor combination therapy
#2500METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY
#2501Methods for treating cancer using TOR kinase inhibitor combination therapy
#2502Treatment of cancer with dihydropyrazino-pyrazines
#2503Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animals
#2504Inhibiting G protein coupled receptor 6 kinase polypeptides
#2505Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules
#2506Methods of treating CXCR4-expressing cancers
#2507DPP-IV INHIBITOR FORMULATIONS
#2508Method for treating a pulmonary hypertension condition
#2509Compounds and methods for treatment of hypertension
#2510Pesticidal compounds
#2511COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE
#2512Compounds useful for treating aids
#2513Methods for the treatment of cardiovascular conditions
#2514USE OF PHOSPHODIESTERASE INHIBITORS FOR TREATING MULTIDRUG RESISTANCE
#2515Substituted [1,2,4]triazolo[1,5-a]pyridines as PDE-10 inhibitors
#2516Therapeutic compositions and methods
#2517Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors
#2518METHODS FOR TREATING HCV
#2519Compositions and methods of treating pulmonary hypertension
#2520METHOD FOR TREATING PULMONARY ARTERIAL HYPERTENSION IN A PATIENT NOT HAVING IDIOPATHIC PULMONARY FIBROSIS
#2521Azetidinyloxyphenylpyrrolidine compounds
#2522METHODS FOR TREATING HCV
#2523Treatment for diabetes in patients inappropriate for metformin therapy
#2524Coated tablets of eszopiclone
#2525FORMULATIONS AND METHODS FOR RAPID PENILE ERECTIONS
#2526Polycyclic pyridone derivative having integrase inhibitory activity
#2527PDE5 inhibitor compositions and methods for immunotherapy
#2528Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
#2529Indole derivatives as selective androgen receptor modulators (SARMS)
#2530Treatment of esophageal motility disorder using sepiapterin, tetrahydrobiopterin and derivatives thereof
#2531Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors
#2532Parenteral formulations of dopamine agonists
#2533PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS WITH ATORVASTATIN
#2534COMPOSITIONS AND METHODS FOR TREATING HERPES VIRUSES
#2535Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors
#2536Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
#2537Combination ALS therapy
#2538Method of enhancing diabetes resolution
#2539Indolyl-substituted pyrazino[1,2-b]isoquinolines for cancer treatment
#2540Composition and methods for the production of S-adenosylmethionine within the body
#2541Ddopamine receptor agonists to treat dyskinesia in parkinson's disease
#2542Methods of treating diabetes
#2543Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors
#2544Alkylated piperazine compounds
#2545Bicyclic compounds and their use as antibacterial agents and betalactamase inhibitors
#2546BTK INHIBITORS
#2547THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE
#2548BTK INHIBITORS
#2549Substituted 6-aza-isoindolin-1-one derivatives
#2550Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
#2551Inhibitors of the renal outer medullary potassium channel
#2552SUPPRESSION OF TOXIN PRODUCTION OF CLOSTRIDIUM DIFFICLE
#2553PHARMACEUTICAL COMPOSITION COMPRISING AN ALGAE ADAPTED TO INCREASE THE EFFICACY OF AN ENZYMATIC INHIBITOR
#2554Substituted naphthyridines for the treatment, amelioration or prevention of a viral disease
#2555COMBINATION PRODUCTS
#2556Tetracyclic compounds
#2557Heteroaryl pyridone and aza-pyridone compounds
#2558Bromocriptine formulations
#2559Preparation of sitagliptin intermediates
#2560Opioid antagonists
#2561NOVEL ERGOLINE DERIVATIVES AND USES THEREOF
#2562Composition for reducing skin wrinkles including PDE5 inhibitor
#2563Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
#2564METHODS FOR TREATING PARKINSON'S DISEASE
#2565PHARMACEUTICAL FORMULATION FOR REDUCING FREQUENCY OF URINATION AND METHOD OF USE THEREOF
#2566PRESELECTION OF SUBJECTS FOR THERAPEUTIC TREATMENT BASED ON HYPOXIC STATUS
#2567Oral pharmaceutical dispersion compositions
#2568Amine-containing lipidoids and uses thereof
#25694-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES BTK INHIBITORS
#25704-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
#2571COMPOUNDS AND METHODS OF TREATING DIABETES
#2572PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME
#2573Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing
#2574THERAPEUTIC COMPOSITIONS
#2575Compositions to effect neuronal growth
#25761-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
#2577Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
#2578Compounds for the treatment of HIV
#2579Uses of DPP IV inhibitors
#2580Benzoxepin PI3K inhibitor compounds and methods of use
#2581ANTIPRURITIC AGENT
#2582PHARMACEUTICAL COMBINATION
#2583METHODS AND COMPOSITIONS FOR TREATING URINARY TRACT INFECTIONS USING AGENTS THAT MIMIC OR ELEVATE CYCLIC AMP
#2584Ophthalmic compositions comprising polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers
#2585Oral Energy Supplement and Related Methods
#2586Pyrrole inhibitors of S-nitrosoglutathione reductase
#2587Substituted imidazo[1,2-a]imidazo[4′,5′:4,5]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections
#2588Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
#2589TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
#2590Process for preparing chiral dipeptidyl peptidase-IV inhibitors
#2591Deuterated pyrazino[2,1-a]isoquinolines for the treatment of diseases and/or conditions
#2592Inhibitor compounds of phosphodiesterase type 10A
#2593Ultra low dose doxepin and methods of using the same to treat sleep disorders
#2594PALATABLE DUCTILE CHEWABLE VETERINARY COMPOSITION
#2595PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS WITH SIMVASTATIN
#2596Method For Treating Erectile Dysfunction
#2597Treatment of erectile dysfunction and other indications
#2598PYRAZOLE DERIVATIVES AS JAK INHIBITORS
#2599Crystalline forms of a dipeptidyl peptidase-IV inhibitor
#2600Particulate materials
#2601Pharmaceutical Formulations Including An Amine Compound
#2602Salts of sitagliptin, process for the preparation and pharmaceutical composition therefore
#2603Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
#2604Azaindole derivatives as tyrosine kinase inhibitors
#2605Methods of treating muscular dystrophy
#2606DIPYRIDINIUM DERIVATIVES
#2607Glucokinase activator compositions for the treatment of diabetes
#2608Pyridone and aza-pyridone compounds and methods of use
#2609BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS
#2610TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS
#2611Substituted imidazo[1,2-a]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections
#2612THERAPEUTIC TREATMENT FOR METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY OR PREDIABETES
#2613Methods and compositions for sleep disorders and other disorders
#2614Bicyclic heterocycle compounds and their uses in therapy
#2615Bicyclic pyridinones
#2616Compositions for treating neurological disorders
#2617Therapeutic and diagnostic methods involving biglycan and utrophin
#2618Inhibitors of protein kinases
#2619Method of treating metabolic disorders and depression with dopamine receptor agonists
#2620PHARMACEUTICAL COMPOSITIONS AND METHODS FOR MAKING AND USING THEM
#2621METHOD FOR TREATING A PULMONARY HYPERTENSION CONDITION WITHOUT COMPANION DIAGNOSIS
#2622COMPOSITIONS AND METHODS FOR TREATING CANCER USING PI3K INHIBITOR AND MEK INHIBITOR
#2623Inhibitors of hepatitis C virus
#2624Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
#2625Anti-viral pyrimidine nucleoside analogues
#2626Treatment of proliferative disorders with a chemiluminescent agent
#2627METHODS AND SYSTEMS FOR TREATMENT OF MIGRAINES AND OTHER INDICATIONS
#2628Inhibitors of phosphodiesterase type 5A for treating or preventing muscle disease or the symptoms thereof in a patient
#2629ORAL PHARMACEUTICAL DISPERSION COMPOSITIONS
#2630SULFONAMIDE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG
#2631Pyrido [2, 3-B] pyrazine compounds and their therapeutical uses such as for inhibiting ATP consuming proteins and treating diseases associated therewith
#2632Biodegradable, water soluble and pH responsive poly(organo)phosphazenes
#2633PHARMACEUTICAL FORMULATION FOR BEDWETTING AND METHOD OF USE THEREOF
#2634FOLIC ACID - RAMIPRIL COMBINATION: CELLPROTECTIVE, NEUROPROTECTIVE AND RETINOPROTECTIVE OPHTALMOLOGIC COMPOSITIONS
#2635NOVEL OPIOID ANTAGONISTS
#2636COMBINATION THERAPY FOR TREATING DIABETES
#2637Pharmaceutical formulation for treating herpes virus infection comprising 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-b) quinoxaline
#2638Quinoxalines and AZA-quinoxalines as CRTHreceptor modulators
#2639NAMPT inhibitors
#2640NAMPT inhibitors
#2641COMPOSITIONS AND METHODS FOR AMELIORATING RENAL DYSFUNCTION INDUCED BY RENAL HYPOPERFUSION OR ACUTE KIDNEY INJURY
#2642NOVEL COMPOSITIONS COMPRISING A PHOSPHODIESTERASE-5 INHIBITOR AND THEIR USE IN METHODS OF TREATMENT
#2643Fused ring compound for use as mineralocorticoid receptor antagonist
#2644Bromocriptine formulations
#2645Pharmaceutical formulation for reducing frequency of urination and method of use thereof
#2646Therapeutic compounds
#2647Therapeutic compounds
#2648Pyridinones/pyrazinones, method of making, and method of use thereof
#2649Compounds and compositions for the treatment of parasitic diseases
#2650Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
#2651CBP/Catenin antagonists for enhancing asymmetric division of somatic stem cells
#2652Therapeutic Treatment for Metabolic Syndrome, Type 2 Diabetes, Obesity, or Prediabetes
#2653Substituted pyrido[2,3-b]pyrazines
#2654PHARMACEUTICAL COMPOSITIONS TO TREAT FIBROSIS
#2655Thiazole derivatives
#2656Treatment of addiction and impulse-control disorders using PDE7 inhibitors
#2657TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
#2658TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
#2659TREATMENT OF CANCER WITH TOR KINASE INHIBITORS
#2660Combination of PPARy Agonist and a Dipeptidyl Peptidase-Inhibitor for the Treatment of Diabetes and Obesity
#2661E-prostanoid receptor, Ptger3, as a novel anti-diabetic therapeutic target
#2662COMPRESSED FORMULATIONS OF ORDERED MESOPOROUS SILICAS
#2663Benzodioxane inhibitors of leukotriene production for combination therapy
#2664Substituted Spiro-Amide Compounds
#2665METHOD FOR TREATING A PULMONARY HYPERTENSION CONDITION WITHOUT COMPANION DIAGNOSIS
#2666Triazolopyrazine derivatives
#2667Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
#2668Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib
#2669METHOD FOR TREATING A PULMONARY HYPERTENSION CONDITION WITHOUT COMPANION DIAGNOSIS
#2670Drug Formulations Using Water Soluble Antioxidants
#2671Substituted 7-(1,2,3-Triazol-4-yl)-pyrrolo[2,3-b]pyrazines
#2672Methods for the treatment of erectile dysfunction using fispemifene
#26733-hydroxyisothiazole 1-oxide derivatives
#2674NOVEL TRICYCLIC COMPOUNDS
#2675THERAPEUTIC COMPOSITIONS
#2676Application of 5-HTreceptor antagonists for the alleviation of cognitive deficits of down syndrome
#2677Substituted imidazopyrazines
#26783-hydroxyisothiazole 1-oxide derivatives
#2679Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors
#2680Veterinary antiprolactinic composition for ruminants
#2681Bicyclic heteroaryl kinase inhibitors and methods of use
#2682Tetracyclic compounds
#2683Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
#2684Treatment of cancer using hypoxia activated prodrugs
#2685Parenteral formulations of dopamine agonists
#2686TRIAZOLOPYRAZINONES AS P2X7 RECEPTOR ANTAGONISTS
#2687Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
#2688Compositions to effect neuronal growth
#2689Tetracyclic compounds
#2690Substituted pyrrolo[2,3-B]pyrazine compounds and their use
#2691Derivatives of betulin
#2692METHODS OF TREATING DIABETIC NEUROPATHY USING BENZENESULFONAMIDES
#2693Pharmaceutical composition containing a tetrahydrofolic acid
#2694DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT
#2695Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
#2696Pharmaceutical Compositions
#2697Method for Inhibiting Transglutaminase 2 Activity Using 2-alkyloxy-3-phenylethynyl-4a,5-dihydropyrido[2,3-b]pyrazine Derivatives
#2698NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES
#2699Respiratory formulations and compounds for use therein
#2700METHODS AND COMPOSITIONS FOR USE IN AQUACULTURE